Mgc Pharmaceuticals Share Price. MXC - Stock Quote, Charts, Trade History, Share Chat, Financials. Mgc Pharmaceuticals Limited

Home
Investing
Stocks
UK
LSE
Mgc Pharmaceuticals Limited (MXC)
Mgc Pharmaceuticals Limited (MXC) Share Price

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Mgc Pharmaceuticals Limited	LSE:MXC	London	Ordinary Share	AU000000MXC6	ORD NPV (DI)

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	0.00	0.0%	0.50	616,924	08:00:00

Bid Price		Offer Price	High Price	Low Price	Open Price
0.45		0.55	0.50	0.50	0.50

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology					14

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
13:40:20	O	100,000	0.52899	GBX

Related Shares
Astrazeneca (AZN), Gsk (GSK), Bermele (BERM), Midatech Pharma (MTPH)

Mgc Pharmaceuticals (MXC) Latest News

Mgc Pharmaceuticals News

Date	Time	Source	Headline
21/3/2023	13:58	ALNC	MGC Pharma's Covid-19 drug ArtemiC available over-the-counter in US
21/3/2023	09:05	UKREG	MGC Pharmaceuticals Limited Second Price Monitoring Extn
21/3/2023	09:00	UKREG	MGC Pharmaceuticals Limited Price Monitoring Extension
21/3/2023	07:00	UKREG	MGC Pharmaceuticals Limited ArtemiC Listed as OTC Drug; AMC Places US$2m..
15/3/2023	16:35	UKREG	MGC Pharmaceuticals Limited Price Monitoring Extension
15/3/2023	15:36	ALNC	TRADING UPDATES: SigmaRoc Sweden boost; Mosman's Cinnabar-1 success
15/3/2023	07:00	UKREG	MGC Pharmaceuticals Limited First patient enrolled in MGC ZAM App
08/3/2023	18:24	ALNC	TRADING UPDATES: Poolbeg patent boost; Resolute Mining resource up
08/3/2023	09:00	UKREG	MGC Pharmaceuticals Limited US$500,000 funding received under Mercer..
07/3/2023	07:00	UKREG	MGC Pharmaceuticals Limited Completion of CimetrA(TM) Mechanism of Action..

More Mgc Pharmaceuticals News

Mgc Pharmaceuticals Investors Mgc Pharmaceuticals Takeover Rumours

Mgc Pharmaceuticals (MXC) Discussions and Chat

Mgc Pharmaceuticals Forums and Chat

Date	Time	Title	Posts
25/3/2023	14:14	MXC Moderated	4,502
22/3/2023	09:05	MXC Going bankrupt Do not buy. loan conversion every month	17
21/3/2023	17:10	Cannabis based medication	4,491
16/11/2022	19:59	MXC Beware of the Ponzi	920
10/7/2022	02:38	MGC Pharmaceuticals LTD	1,069

Add a New Thread

Mgc Pharmaceuticals (MXC) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
12:40:22	0.53	100,000	528.99	O
11:49:47	0.53	1,872	10.00	O
11:47:06	0.53	121,533	644.00	O
11:40:15	0.47	663	3.14	O
11:16:01	0.47	39	0.18	O

View all Mgc Pharmaceuticals trades in real-time

Mgc Pharmaceuticals (MXC) Top Chat Posts

Top Posts
Posted at 22/3/2023 10:01 by the mugger Funding 01/03/2023 7:02am UK Regulatory (RNS & others) Mgc Pharmaceuticals (LSE:MXC) Historical Stock Chart From Feb 2023 to Mar 2023 Click Here for more Mgc Pharmaceuticals Charts. TIDMMXC RNS Number : 4761R MGC Pharmaceuticals Limited 01 March 2023 MGC Pharmaceuticals Ltd. Appointment of UK Lead Broker and Change of Company Secretary 01 March 2023 ASX, LSE: MXC MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') is pleased to announce the appointment of UK based Peterhouse Capital as the Company's lead broker on the LSE, with immediate effect, replacing Turner Pope. This appointment is part of the Company's UK focused corporate strategy with respect to future equity capital market financings and corporate opportunities. MGC Pharma's non-executive chairman, Mr Brett Mitchell, commented "The board is very pleased to welcome the appointment of Peterhouse Capital as lead broker for the LSE to play a key role in the company's future funding strategies and corporate opportunities. In addition, we would also like to thank Mr David Lim for his dedication and commitment to the Company, and the board wishes him every success with his next venture." --Ends-- Read Full Thread Follow Reply
Posted at 22/3/2023 09:08 by the mugger Beware forward selling. Look at the many previous rns, another one is due in 2 weeks MGC Pharmaceuticals Limited US$10m Financing Agreement with Mercer Street 29/07/2022 7:00am UK Regulatory (RNS & others) Mgc Pharmaceuticals (LSE:MXC) Historical Stock Chart From Mar 2022 to Mar 2023 Click Here for more Mgc Pharmaceuticals Charts. TIDMMXC RNS Number : 2251U MGC Pharmaceuticals Limited 29 July 2022 MGC Pharmaceuticals Ltd. New US$10m Financing Agreement signed with US-based Strategic Fund and Largest Shareholder, Mercer Street Capital 29 July 2022 ASX, LSE: MXC MGC Pharmaceuticals Ltd (ASX, LSE: MXC, 'MGC Pharma' or 'the Company'), a European based bio-pharma company specialising in the production and development of phytomedicines, is pleased to announce that it has entered into a new convertible securities financing agreement (Financing Agreement) with Mercer Street Global Opportunity Fund, LLC, a fund managed by Mercer Street Capital Partners, LLC, a United States-based institutional fund manager (together, "Mercer") and MGC Pharma's largest shareholder, to provide the Company with a substantial funding facility of up to a total of US$10m. This fully funds the current MGC Pharma business plan and replaces the unused amount of the convertible facility announced in September 2020[1] , providing MGC with material financing facility to be drawn on as required to execute its strategy. The first tranche of US$1.20 million will be provided to the Company upon satisfaction of the closing conditions (including lodging a cleansing statement), through the issue of 1.32M convertible notes with a face value of US$1 each to Mercer Street ( Tranche 1 Notes ). This US$10m financing facility provides MGC Pharma with access to significant capital in order to execute its business commercialisation strategy primarily, with Sciensus Rare in the UK and EU and AMC in the USA, as well as advance the regulatory approvals for the Company's proprietary products to drive revenues, assist in the rollout of the ZAM App and provide funding for the Group's general corporate expenses. The Company will continue implement significant non revenue driving cost controls, as announced in it recent June Quarter Activities Report, within the operations including the delay of non-core clinical trials, and will look to use funding under this agreement selectively to support new growth and strategic initiatives. Key Terms The key terms of the Financing Agreement are set out below: -- Convertible Securities facility of up to $US10m in total. -- The initial tranche of convertible securities issued will provide funding of US$1.2m to MGC Pharma. In addition, the company will issue 21,511,545 fully paid ordinary shares to Mercer in consideration for the provision of funding. Both issues will be made utilising MGC Pharma's existing capacity. -- Subsequent tranches of funding are available up to a value of US$8.8m within 18 months of execution of the agreement, with access to the additional funding subject to normal conditions precedent for a facility of this nature including MGC Pharma having sufficient capacity under Chapter 7 of the Listing Rules to issue the convertible notes or shareholder approval being obtained. -- For each US$1.00 of funding provided to MGC Pharma, the Company will issue Mercer Convertible Securities to the value of US$1.10. -- The value of outstanding Convertible Securities held by Mercer can: Read Full Thread Follow Reply
Posted at 06/3/2023 23:35 by looneytune More good news:- 7 March 2023 ASX Code: MXC LSE Code: MXC Completion of CimetrATM Mechanism of Action study Key Highlights: • • • • • TM’s ability MGC Pharma has completed an in-vitro pre-clinical study on CimetrATM’s mechanism of action (MoA) The study, which was carried out at the GLP-Certified Science in Action Lab, in Ness Ziona, Israel, examined the mechanism underlying the CimetrATM-mediated anti-inflammatory effect on human Peripheral Blood Mononuclear Cells (PBMC) The study demonstrated the inhibitory effect of CimetrATM on the mRNA expression and, as a result, on the secretion of IL-32 proteins and the subsequent suppression of inflammation and inflammatory cytokines Additional findings show that CimetrATM increases intracellular HO-1 the antioxidant activity in cells, protecting against oxidative stress that causes the inflammation Further demonstrates CimetrA to be extended into the anti-inflammatory market MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has completed the pre-clinical study on CimetrATM, exploring the Mechanism of Action (MoA) of the product. The study was conducted on human Peripheral Blood Mononuclear Cells (PBMC) crucial in the immune response, the results of which are consistent with previous reports. The administration of CimetrATM before and during Lipopolysaccharide (LPS) stimulation to produce an immune response and induce cytokine generation, resulted in a significant decrease in IL-32 mRNA expression and a resulting decrease in inflammation. As such, we conclude that the presence of the IL-32 mRNA protein plays a critical role in the secretion of the cytokines (Figure 1), such as tumour necrosis factor-alpha (TNF-α) and IL-6 (Figure 2), that cause inflammation. Control of this protein is then the fundamental pathway to manage and reduce inflammation. The preclinical study demonstrates that the Mechanism of Action in MGC’s core development product, CimetrATM is the suppression of IL-32 protein via effect on the mRNA expression. The graph below demonstrates the decreased (up to undetectable values) IL-32A level after the treatment of the PBMC induced tissue with CimetrA in comparison with the baseline (LPS column), Placebo treatment and not treated control. Link to article https://investi.com.au/api/announcements/mxc/f9bfd166-a6c.pdf Read Full Thread Follow Reply
Posted at 01/3/2023 07:35 by looneytune MGC Pharmaceuticals Limited Appointment of UK Lead Broker and Change of Co Sec 01/03/2023 7:02am UK Regulatory (RNS & others) Mgc Pharmaceuticals (LSE:MXC) Intraday Stock Chart Wednesday 1 March 2023 Click Here for more Mgc Pharmaceuticals Charts. TIDMMXC RNS Number : 4761R MGC Pharmaceuticals Limited 01 March 2023 MGC Pharmaceuticals Ltd. Appointment of UK Lead Broker and Change of Company Secretary 01 March 2023 ASX, LSE: MXC MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') is pleased to announce the appointment of UK based Peterhouse Capital as the Company's lead broker on the LSE, with immediate effect, replacing Turner Pope. This appointment is part of the Company's UK focused corporate strategy with respect to future equity capital market financings and corporate opportunities. The Company also advises that Mr David Lim, MGC Pharma's Company Secretary, has retired from the position. Mr Lim has overseen the transition of the Company's corporate compliance structure to one that is significantly more organised and well positioned for the future. Mr Lim is replaced as MGC Pharma's Company Secretary by Messrs Rowan Harland and Arron Canicais of SmallCap Corporate Pty Ltd, a Perth based corporate advisory firm, who have been appointed Joint Company Secretaries effective today. MGC Pharma's non-executive chairman, Mr Brett Mitchell, commented "The board is very pleased to welcome the appointment of Peterhouse Capital as lead broker for the LSE to play a key role in the company's future funding strategies and corporate opportunities. In addition, we would also like to thank Mr David Lim for his dedication and commitment to the Company, and the board wishes him every success with his next venture." --Ends-- Read Full Thread Follow Reply
Posted at 22/2/2023 18:39 by goforgold1 nd thus MGC remains reliant on an extremely onerous death spiral provided by the sharks at Mercer. The last draw down was of $600,000, call it £500,000 on February 3.This is a business that in the last quarter to December 31 2022 showed an underlying cashburn of £600,000 a month! The company drew down an $800,000 tranche of death spiral on December 28 but that was all gone by February 3 when that £500,000 drawdown took place. My cat can do the maths: the next drawdown and associated forward selling is now imminent. Hence the share price dump. Read Full Thread Follow Reply
Posted at 09/1/2023 22:00 by looneytune News incoming:- https://investi.com.au/api/announcements/mxc/c3c6a23e-98c.pdf January 2023 ASX Code: MXC LSE Code: MXC Completion of CimetrATM bioanalytics Pre-clinical Trial Key Highlights: • • • • • • • MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has completed the pre-clinical rodent studies on CimetrATM, which are a key step in the clinical pathway prior to the planned FDA Investigational New Drug submission. Research using rodent and mammalian models are used to delineate the pharmacokinetic profile and general safety of a drug, as well as to identify toxicity patterns over a given period for the treatment before it advances to the next stage of trials, as required by US Food and Drug Administration (FDA) criteria. The Study was undertaken to determine toxicological effects of CimetrATM over a 14-day period in rats, and was undertaken by the Smart Assays and Science in Action Laboratories in Israel, and comprised four study groups, three separate dosage groups, and one control group, with the treatment administered over a period of fourteen days, followed by a seven day review period. Blood samples for the pharmacokinetic analysis were taken on a daily basis, and histopathology tests were conducted on all organs per FDA guidelines. No anomalies were observed in the biopsies taken, nor were any clinical or behavioural adverse events recorded. This Study is crucially important in the regulatory approval process for Investigational New Drugs (IND) approval by the FDA, and forms a key part of the metrics for the FDA's Center for Drug Evaluation and Research (CDER), the commercial and consumer watchdog, and gatekeeper to the US pharmaceutical market. There is a strict process for FDA approval: discovery, preclinical development, and clinical trial, where the boundary between preclinical development and clinical trial is sharply defined by the IND approval. Final FDA approvals will ensure that CimetrATM meets the criteria for further clinical study and 1 - 7 MGC Pharma has completed the full pre-clinical rodents study panel for CimetrATM. The latest study, which was carried out at the Smart Assays laboratory in Israel, included the development of bioanalytical methods and validations for further pharmacokinetic analysis for CimetrATM. A study on chronic toxicity in rodents was also completed by Science in Action, in Israel, monitoring the potential development of adverse effects from using CimetrATM. Histopathology demonstrated the full safety profile for CimetrATM across all study dosage groups. The study results are an important step ahead of the submission to the US Food and Drug Administration (FDA) for Investigational New Drug (IND) approval. No anomalies were observed in the biopsies, nor were any clinical or behavioural adverse events recorded. CimetrATM is MGC Pharma’s proprietary Investigational Medicinal Product which in previous clinical trials has demonstrated anti-inflammatory and immunomodulating properties, and is MGC’s most clinically advanced product. development in the US, and ultimately commercial sale, therefore opening up the largest healthcare market globally to MGC Pharma. Roby Zomer, co-founder, Managing Director and CEO of MGC Pharmaceuticals, commented: “The successful completion of this study and the excellent results attained is an important milestone moment for the Company, as we continue to progress CimetrATM along the mandated clinical pathway. The results of this study are a critical step in advancing MGC’s submission to the FDA, and for the final approval of CimetrATM as an Investigational New Drug in the US.” A summary of results from the recently completed study can be found in Annexure A below. About CimetrATM CimetrATM is a nanoparticle micellar formulation based on the pharmaceutical synergetic composition consisting of Curcumin and Boswellia. In pre-clinical and clinical trials CimetrATM has demonstrated anti- inflammatory and immunomodulating effects, and can be designed for multiple therapeutic applications utilising Graft Polymer IP Ltd’s proprietary GraftBioTM Self-nano-emulsifying Drug Delivery System. Preclinical and clinical results to date have demonstrated CimetrATM's mechanism of action as an anti- inflammatory and immunomodulatory agent which is effective in the prevention of severe inflammation by its control of increased Cytokine production resulting from an infection of the different variants of SARS-CoV-2 (the virus responsible for COVID-19); and which is the forerunner of a Cytokine Storm, which is believed to be the main reason for mortality in severe COVID-19 patients. Authorised for release by the Board, for further information please contact: MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 info@mgcpharma.com.au UK Financial and Corporate Advisor Hannam & Partners Rupert Fane / Nilesh Patel +44 7810 056 104 rf@hannam.partners / nilesh@hannam.partners UK PR Advisors Tavistock Charles Vivian / Tim Pearson +44 207 920 3150 mgcpharma@tavistock.co.uk About MGC Pharma MGC Pharmaceuticals Ltd David Lim Company Secretary +61 8 6382 3390 info@mgcpharma.com.au UK Broker Turner Pope Andy Thacker +44 203 657 0050 info@turnerpope.com MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on develo Read Full Thread Follow Reply
Posted at 07/12/2022 06:13 by looneytune 7 December 2022 ASX Code: MXC LSE Code: MXC Completion of CimetrATM Efficacy Pre-clinical Trial Key Highlights: • A pre-clinical study has now been completed on a model of cytokine storm in rodents using the CimetrATM formulation, and has demonstrated an anti-inflammatory effect in three different dosages of treatments. • The study results demonstrate CimetrATM’s effect on the anti-inflammatory and pro-inflammatory cytokines and chemokines which support the previous anti-inflammatory results of CimetrATM. • The study results will form part of the US Food and Drug Administration (FDA) application to register CimetrATM as an Investigational New Drug (IND), and is a critical milestone in the process of drug registration. MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’), a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has completed pre-clinical trial testing the efficacy of the CimetrATM formulation on rodents exhibiting the cytokine storm, in order to measure the anti-inflammatory effects of three different dosages. The trial, carried out at the GLP-certified Science in Action Laboratory in Ness Ziona, Israel, demonstrated the anti-inflammatory effect of the treatment, with the histopathology showing the reduction of lung inflammation resulting from the onset of a cytokine storm1, in comparison to the control group. This was measured through the relative protein concentration of the cellular and acellular concentrations of the lung system. This study is the next step in the regulatory process for Investigational New Drug (IND) approval, and is one of a cohort of studies needed to evaluate safety and efficacy in preclinical and clinical models. An IND application is expected to be submitted Q1 2023 for CimetrATM, as set out in prior company releases. Through these studies, CimetrATM has been shown to reduce the production of Interleukin 1α (IL-1α), an inflammatory cytokine responsible for activating the escalation of disease manifested in the form of severe acute or chronic inflammation. Study groups included Naïve, LPS, LPS solvent PBS, LPS+CimetrATM 48 μg, LPS+CimetrATM 96 μg, LPS+CimetrATM 192 μg. The graph displaying the results for each study group, control and treatment, is shown below: 1 Cytokine Storm: A severe immune overreaction in which the body releases higher than normal levels of inflammatory cytokines into info@mgcpharma.eu \| mgcpharma.co.uk 1 the blood too quickly MGC Pharmaceuticals Ltd \| 1202 Hay Street, West Perth, WA 6005 PO Box 1976, West Perth WA 6872 T: +61 8 6382 3390 - 3 Secondary test work illustrated the effect of CimetrATM on the Macrophage inflammatory protein-1 alpha (MIP-1α/CCL3), which is a chemotactic chemokine secreted by macrophages – the white blood cells that stimulate the body’s immune system. The protein performs various biological functions, such as recruiting inflammatory cells, wound healing, inhibition of stem cells, and maintaining effector immune response. IL-17 has anti-inflammatory activity and this cytokine can suppress the development of autoimmune and inflammatory disease. The study was completed on 55 rodents and the results presented efficacy results are statistically significant (p<0.05). This model demonstrates the anti-inflammatory mechanism of action of CimetrATM and will support the future definition of the clinical program, based on the cytokines that were affected by the drug. Roby Zomer, co-founder and Managing Director of MGC Pharmaceuticals, commented: “The completion of this study is critical in the advancement of our submission to the FDA and for the final approval of CimetrATM as an IND in the US. There are further efficacy and safety trials to support our application, but these results are key step in the demonstration of CimetrATM as a treatment for the symptoms of the cytokine storm.” --Ends-- 2 - 3 Authorised for release by the Managing Director, for further information please contact: MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 info@mgcpharma.eu UK Financial and Corporate Advisor Hannam & Partners Rupert Fane / Nilesh Patel +44 7810 056 104 rf@hannam.partners / nilesh@hannam.partners UK PR Advisors Tavistock Charles Vivian / Tim Pearson +44 207 920 3150 mgcpharma@tavistock.co.uk About MGC Pharma MGC Pharmaceuticals Ltd David Lim Company Secretary +61 8 6382 3390 info@mgcpharma.eu UK Broker Turner Pope Andy Thacker +44 203 657 0050 info@turnerpope.com MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceuticals company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions. The Company’s founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development. MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company’s EU-GMP Certified manufacturing facilities. MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. Follow us through our social media channels Read Full Thread Follow Reply
Posted at 07/12/2022 06:05 by looneytune https://investi.com.au/api/announcements/mxc/cd1347ff-cf2.pdf 7 December 2022 ASX Code: MXC LSE Code: MXC Completion of CimetrATM Efficacy Pre-clinical Trial Key Highlights: • A pre-clinical study has now been completed on a model of cytokine storm in rodents using the CimetrATM formulation, and has demonstrated an anti-inflammatory effect in three different dosages of treatments. • The study results demonstrate CimetrATM’s effect on the anti-inflammatory and pro-inflammatory cytokines and chemokines which support the previous anti-inflammatory results of CimetrATM. • The study results will form part of the US Food and Drug Administration (FDA) application to register CimetrATM as an Investigational New Drug (IND), and is a critical milestone in the process of drug registration. MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’), a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has completed pre-clinical trial testing the efficacy of the CimetrATM formulation on rodents exhibiting the cytokine storm, in order to measure the anti-inflammatory effects of three different dosages. The trial, carried out at the GLP-certified Science in Action Laboratory in Ness Ziona, Israel, demonstrated the anti-inflammatory effect of the treatment, with the histopathology showing the reduction of lung inflammation resulting from the onset of a cytokine storm1, in comparison to the control group. This was measured through the relative protein concentration of the cellular and acellular concentrations of the lung system. This study is the next step in the regulatory process for Investigational New Drug (IND) approval, and is one of a cohort of studies needed to evaluate safety and efficacy in preclinical and clinical models. An IND application is expected to be submitted Q1 2023 for CimetrATM, as set out in prior company releases. Through these studies, CimetrATM has been shown to reduce the production of Interleukin 1α (IL-1α), an inflammatory cytokine responsible for activating the escalation of disease manifested in the form of severe acute or chronic inflammation. Study groups included Naïve, LPS, LPS solvent PBS, LPS+CimetrATM 48 μg, LPS+CimetrATM 96 μg, LPS+CimetrATM 192 μg. The graph displaying the results for each study group, control and treatment, is shown below: 1 Cytokine Storm: A severe immune overreaction in which the body releases higher than normal levels of inflammatory cytokines into info@mgcpharma.eu \| mgcpharma.co.uk 1 the blood too quickly MGC Pharmaceuticals Ltd \| 1202 Hay Street, West Perth, WA 6005 PO Box 1976, West Perth WA 6872 T: +61 8 6382 3390 - 3 Secondary test work illustrated the effect of CimetrATM on the Macrophage inflammatory protein-1 alpha (MIP-1α/CCL3), which is a chemotactic chemokine secreted by macrophages – the white blood cells that stimulate the body’s immune system. The protein performs various biological functions, such as recruiting inflammatory cells, wound healing, inhibition of stem cells, and maintaining effector immune response. IL-17 has anti-inflammatory activity and this cytokine can suppress the development of autoimmune and inflammatory disease. The study was completed on 55 rodents and the results presented efficacy results are statistically significant (p<0.05). This model demonstrates the anti-inflammatory mechanism of action of CimetrATM and will support the future definition of the clinical program, based on the cytokines that were affected by the drug. Roby Zomer, co-founder and Managing Director of MGC Pharmaceuticals, commented: “The completion of this study is critical in the advancement of our submission to the FDA and for the final approval of CimetrATM as an IND in the US. There are further efficacy and safety trials to support our application, but these results are key step in the demonstration of CimetrATM as a treatment for the symptoms of the cytokine storm.” --Ends-- 2 - 3 Authorised for release by the Managing Director, for further information please contact: MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 info@mgcpharma.eu UK Financial and Corporate Advisor Hannam & Partners Rupert Fane / Nilesh Patel +44 7810 056 104 rf@hannam.partners / nilesh@hannam.partners UK PR Advisors Tavistock Charles Vivian / Tim Pearson +44 207 920 3150 mgcpharma@tavistock.co.uk About MGC Pharma MGC Pharmaceuticals Ltd David Lim Company Secretary +61 8 6382 3390 info@mgcpharma.eu UK Broker Turner Pope Andy Thacker +44 203 657 0050 info@turnerpope.com MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceuticals company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions. The Company’s founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development. MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company’s EU-GMP Certified manufacturing facilities. MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. Follow us through our social media channels Read Full Thread Follow Reply
Posted at 26/8/2022 08:43 by looneytune Application for quotation of +securities Announcement Summary Entity name MGC PHARMACEUTICALS LTD Announcement Type New announcement Date of this announcement Friday August 26, 2022 The +securities to be quoted are: Other Total number of +securities to be quoted ASX +security code MXC Security description ORDINARY FULLY PAID Number of +securities to be quoted 20,000,000 Issue date 26/08/2022 Refer to next page for full details of the announcement Application for quotation of +securities 1 / 6 Application for quotation of +securities Part 1 - Entity and announcement details 1.1 Name of entity MGC PHARMACEUTICALS LTD We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules. 1.2 Registered number type ABN 1.3 ASX issuer code MXC 1.4 The announcement is New announcement 1.5 Date of this announcement 26/8/2022 Registration number 30116800269 Application for quotation of +securities 2 / 6 Application for quotation of +securities Part 2 - Type of Issue 2.1 The +securities to be quoted are: Other 2.2 The +securities to be quoted are: Additional +securities in a class that is already quoted on ASX ("existing class") 2.3c Have these +securities been offered under a +disclosure document or +PDS? No 2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B The securities have been issued in lieu of payments to employee/consultants of the Company in order for the Company to preserve working capital. Approval to issue the securities was received after business hours on the 25/8/22, as such an Appendix 3B was not deemed necessary as an Appendix 2A would be released on the same day as the Appendix 3B. 2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of: The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f) Application for quotation of +securities 3 / 6 Application for quotation of +securities Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B Additional +securities to be quoted in an existing class ASX +security code and description MXC : ORDINARY FULLY PAID Issue date 26/8/2022 Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class? Yes Issue details Number of +securities to be quoted 20,000,000 Are the +securities being issued for a cash consideration? No Please describe the consideration being provided for the +securities The securities are being issued to employees/consultants for services rendered in lieu of cash payment. Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted 0.019000 Any other information the entity wishes to provide about the +securities to be quoted The purpose(s) for which the entity is issuing the securities To pay for services rendered Please provide additional details The securities are being issued to employees/consultants for services rendered in lieu of cash payment. Application for quotation of +securities 4 / 6 Application for quotation of +securities Part 4 - Issued capital following quotation 4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application) Total number of ASX +security code and description +securities on issue Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise: (A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.) MXC : ORDINARY FULLY PAID 4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX) 2,850,647,321 ASX +security code and description MXCAF : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES MXCAG : PERFORMANCE RIGHTS MXCAAA : CONVERTIBLE NOTES MXCAAC : CLASS B PERFORMANCE RIGHTS MXCAAD : CLASS C PERFORMANCE RIGHTS MXCAH : OPTION EXPIRING 31-MAR-2023 EX $0.026 MXCAI : OPTION EXPIRING 31-MAR-2023 EX GBP0.01475 MXCAAE : CLASS D PERFORMANCE RIGHTS MXCAAF : CLASS E PERFORMANCE RIGHTS Total number of +securities on issue 60,300,000 22,275,000 3,420,000 39,900,000 6,000,000 7,692,308 26,440,678 250,000 250,000 Application for quotation of +securities 5 / 6 Application for quotation of +securities Part 5 - Other Listing Rule requirements No 5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1? No 5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? Yes 5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? 20,000,000 5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? No 5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1? Application for quotation of +securities 6 / 6 Read Full Thread Follow Reply
Posted at 29/7/2022 06:24 by looneytune 29 July 2022 ASX Code: MXC LSE Code: MXC 1 See announcement 10th September 2020 1 - 3 New US$10m Financing Agreement signed with US-based Strategic Fund and Largest Shareholder, Mercer Street MGC Pharmaceuticals Ltd (ASX, LSE: MXC, ‘MGC Pharma’ or ‘the Company’), a European based bio- pharma company specialising in the production and development of phytomedicines, is pleased to announce that it has entered into a new convertible securities financing agreement (Financing Agreement) with Mercer Street Global Opportunity Fund, LLC, a fund managed by Mercer Street Capital Partners, LLC, a United States-based institutional fund manager (together, “Mercer”) and MGC Pharma’s largest shareholder, to provide the Company with a substantial funding facility of up to a total of US$10m. This fully funds the current MGC Pharma business plan and replaces the unused amount of the convertible facility announced in September 20201 , providing MGC with material financing facility to be drawn on as required to execute its strategy. The first tranche of US$1.20 million will be provided to the Company upon satisfaction of the closing conditions (including lodging a cleansing statement), through the issue of 1.32M convertible notes with a face value of US$1 each to Mercer Street (Tranche 1 Notes). This US$10m financing facility provides MGC Pharma with access to significant capital in order to execute its business commercialisation strategy primarily, with Sciensus Rare in the UK and EU and AMC in the USA, as well as advance the regulatory approvals for the Company’s proprietary products to drive revenues, assist in the rollout of the ZAM App and provide funding for the Group’s general corporate expenses. The Company will continue implement significant non revenue driving cost controls, as announced in it recent June Quarter Activities Report, within the operations including the delay of non-core clinical trials, and will look to use funding under this agreement selectively to support new growth and strategic initiatives. Key Terms The key terms of the Financing Agreement are set out below: • Convertible Securities facility of up to $US10M in total. • The initial tranche of convertible securities issued will provide funding of US$1.2M to MGC Pharma. In addition, the company will issue 21,511,545 fully paid ordinary shares to Mercer in consideration for the provision of funding. Both issues will be made utilising MGC Pharma’s existing capacity. • Subsequent tranches of funding are available up to a value of US$8.8M within 18 months of execution of the agreement, with access to the additional funding subject to normal conditions precedent for a facility of this nature including MGC Pharma having sufficient capacity under Chapter 7 of the Listing Rules to issue the convertible notes or shareholder approval being obtained. • For each US$1.00 of funding provided to MGC Pharma, the Company will issue Mercer Convertible Securities to the value of US$1.10. • The value of outstanding Convertible Securities held by Mercer can: o AttheelectionofMercer,beconvertedintofullypaidordinarysharesinMGC Pharma; Capital o At the election of MGC Pharma, be repurchased at a premium of 3% to the value of the convertible securities, subject to Mercer having the right to first convert 30% of the elected repurchase amount. o If Mercer have not converted any outstanding convertible securities prior to 10 business days prior to their maturity, MGC Pharma must repay the value of the maturing convertible notes in cash. • Conversion of convertible securities by Mercer will be at a discount to the lowest daily VWAP, for the 10 Business Days prior to the Conversion Date. For the first tranche of notes (1.32million US$1.00 notes) any conversion within the first two months will have a conversion price of AU$0.20. After this, the conversion price will be the lower of AU$0.02 or 92% of the lowest daily VWAP selected by Mercer over the 10 prior days of trading, subject to the conversion price being no less than AU$0.014. The conversion price of any subsequent tranches will be the lower of AU$0.02 or 90% of the lowest daily VWAP selected by Mercer over the 10 prior days of trading, subject to the conversion price being no less than AU$0.014. • The term of each of the convertible notes is 18 months from their issue. The outstanding convertible securities are secured by a first ranking general security charge over the assets of MGC Pharma. • The agreement may be terminated on the happening of a number of events including (but not limited to) by Mercer if a condition is not satisfied, an event of default occurs, by the mutual written consent of the parties or by MGC Pharma only after the issue of the first tranche of convertible securities and the commencement shares. The agreement otherwise contains representations, warranties and indemnity which are considered standard for an agreement of this nature. Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: “This US$10m agreement is testament to the progress we have made over the last 18 months. The partnership with Mercer will allow us to fast track our commercial and clinical activities, and advance our company growth strategy.” --Ends-- Authorised for release by the Board, for further information please contact: Jonathan Juchno, Managing Partner, Mercer Street, commented: “Having been a shareholder for the last two years, we have been fortunate to witness first-hand the progress made by MGC Pharma and we are excited to continue our relationship with them and to support the efforts of management in bringing their products to market.” MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 info@mgcpharma.com.au UK Broker – Turner Pope Andy Thacker +44 203 657 0050 info@turnerpope.com About MGC Pharma MGC Pharmaceuticals Ltd David Lim Company Secretary +61 8 6382 3390 info@mgcpharma.com.au UK PR Advisors – Tavistock Charles Vivian /Tim Pearson +44 207 920 3150 mgcpharma@tavistock.co.uk MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline. Employing its ‘Nature to Medicine’ strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company’s EU- GMP Certified manufacturing facility. 2 - 3 MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour. MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. Follow us through our social media channels 3 - 3 Read Full Thread Follow Reply

Mgc Pharmaceuticals share price data is direct from the London Stock Exchange

Your Recent History

LSE

MXC

Mgc Pharma..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V: D:20230328 13:03:42